FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
26 May 2020 10:30 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 21 May 2020, Pascal
Soriot, Chief Executive Officer, was granted an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) under the
terms of the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
PDMR
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
Pascal
Soriot
|
8,734
|
£73.76
|
This award forms part of the AZPSP award granted to Mr Soriot on 6
March 2020 and has been made to take account of the revised limits
for the AZPSP approved by shareholders at the Company's 2020 Annual
General Meeting. As such, it is subject to a combination of
performance measures focused on scientific, commercial and
financial performance assessed over a three-year performance period
(1 January 2020 to 31 December 2022). The Ordinary Shares granted
under the AZPSP are subject to a two-year holding period following
the performance period, and are due to vest on the fifth
anniversary of grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2019, which is
available on the Company's website at
www.astrazeneca.com/annualreport2019.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Pascal
Soriot
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief
Executive Officer
|
b)
|
Initial notification /Amendment
|
Initial
notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca
PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Grant of
a share award under the AstraZeneca Performance Share
Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
£73.76
|
8,734
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
21 May
2020
|
f)
|
Place of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
26 May
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|